Cpmg Inc Buys 200,000 Shares of Reata Pharmaceuticals Inc (RETA) Stock

Reata Pharmaceuticals Inc (NASDAQ:RETA) Director Cpmg Inc bought 200,000 shares of Reata Pharmaceuticals stock in a transaction dated Thursday, December 14th. The stock was acquired at an average cost of $24.79 per share, with a total value of $4,958,000.00. Following the completion of the acquisition, the director now directly owns 113 shares of the company’s stock, valued at approximately $2,801.27. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Reata Pharmaceuticals Inc (NASDAQ:RETA) opened at $25.10 on Friday. Reata Pharmaceuticals Inc has a one year low of $19.48 and a one year high of $40.88. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of -0.15.

Reata Pharmaceuticals (NASDAQ:RETA) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). The firm had revenue of $12.60 million for the quarter, compared to analyst estimates of $12.54 million. The company’s revenue for the quarter was up .0% compared to the same quarter last year. sell-side analysts expect that Reata Pharmaceuticals Inc will post -1.91 earnings per share for the current year.

Several institutional investors have recently modified their holdings of RETA. Geode Capital Management LLC increased its stake in shares of Reata Pharmaceuticals by 19.5% during the first quarter. Geode Capital Management LLC now owns 63,778 shares of the company’s stock worth $1,444,000 after acquiring an additional 10,397 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Reata Pharmaceuticals during the first quarter worth about $559,000. Russell Investments Group Ltd. acquired a new position in shares of Reata Pharmaceuticals during the second quarter worth about $254,000. Strs Ohio increased its stake in shares of Reata Pharmaceuticals by 220.6% during the second quarter. Strs Ohio now owns 21,800 shares of the company’s stock worth $689,000 after acquiring an additional 15,000 shares during the period. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Reata Pharmaceuticals by 44.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 27,200 shares of the company’s stock worth $861,000 after acquiring an additional 8,400 shares during the period. Institutional investors and hedge funds own 29.61% of the company’s stock.

A number of equities research analysts have recently commented on the stock. Cowen reaffirmed a “buy” rating on shares of Reata Pharmaceuticals in a report on Thursday. Leerink Swann assumed coverage on shares of Reata Pharmaceuticals in a report on Wednesday, September 13th. They issued an “outperform” rating and a $43.00 target price for the company. Jefferies Group assumed coverage on shares of Reata Pharmaceuticals in a report on Wednesday, August 30th. They issued a “buy” rating and a $44.00 target price for the company. ValuEngine cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, November 9th. Finally, BidaskClub cut shares of Reata Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 5th. Three equities research analysts have rated the stock with a sell rating and eight have given a buy rating to the company’s stock. Reata Pharmaceuticals presently has an average rating of “Hold” and an average price target of $54.71.

ILLEGAL ACTIVITY WARNING: This news story was originally posted by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this news story on another website, it was stolen and republished in violation of US and international copyright and trademark legislation. The legal version of this news story can be accessed at https://stocknewstimes.com/2017/12/17/cpmg-inc-buys-200000-shares-of-reata-pharmaceuticals-inc-reta-stock.html.

Reata Pharmaceuticals Company Profile

Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.

Insider Buying and Selling by Quarter for Reata Pharmaceuticals (NASDAQ:RETA)

Receive News & Ratings for Reata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply